News | March 17, 2015

CMS Opens Comment Period for Reconsideration of NaF-18 PET National Coverage Determination Manual

Agency seeking feedback on data collection requirements for use of PET in finding bone cancer metastasis

NOPR, CMS, PET, NaF-18, comment period, bone metastasis

March 17, 2015 — The National Oncologic PET Registry (NOPR) Working Group submitted a formal request to the Centers for Medicare and Medicaid Services (CMS), to end the prospective data collection requirements under Coverage with Evidence Development (CED) for use of NaF-18 PET (CAG-00065R) imaging in intended patient management. CMS has initiated its review of this request.

Positron emission tomography (PET) is a minimally invasive imaging procedure used to assess metabolic activity and perfusion in various organs or tissues. Images are obtained by processing of emissions from positron-emitting radioisotopes that are usually administered intravenously. Sodium fluoride F-18 (NaF-18) is a radioisotope commonly used in oncologic PET imaging procedures to detect bone metastasis in cancer and is the focus of this national coverage analysis.

The rate of NaF-19 uptake provides information on the tissues being studied. NaF-18 PET evaluation can indicate the probable presence or absence of bone metastasis based upon observed differences in biologic activity of adjacent tissues.

Section 220.6.19 of the National Coverage Determination (NCD) Manual establishes the requirement for prospective data collection under CED for NaF-18 PET for bone metastasis in cancer.

At this time, CMS is soliciting comments on the NOPR's request. The public comment period will be open for 30 days, until April 16, 2015. PET facilities participating in the NOPR are encouraged to provide comments (which can be entered directly online on the CMS website at this link). Additionally, PET facilities are encouraged to ask referring physicians who frequently use NaF-18 PET in the care of their patients to submit comments to CMS indicating how NaF-18 PET has helped with patient management. Comments that cite scientific evidence (including unpublished data), including the full range of uses of NaF-18 PET in oncology and the uses of NaF-18 PET in benign bone and joint diseases, will be particularly valuable to CMS.  

For more information: www.cms.gov

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init